BIVI
BIOVIE INC.Company Information
- Company Name
- BIOVIE INC.
- CIK
- CIK0001580149
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- BIVI: Nasdaq, BIVIW: Nasdaq
- Fiscal Year End
- June 30
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- BIVI
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-08-28
- Last sale
- 2023-12-01
- Shares purchased (TTM)
- 23,280
- Shares sold (TTM)
- 0
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 1,407,971
- Shares outstanding
- 7,245,928
- Ownership
- 19.43%
Earnings Market Reaction
- Filing date
- 2026-08-13
- Price on filing date
- —
- 1-month reaction
- 28.21%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 9 | 13 | 21 | 25 | 18 | 23 | 24 | 20 | 24 | 30 | 20 | 21 | ||||||
| Grants Receivable Current | - | - | - | 0 | 2 | - | - | - | - | - | - | - | ||||||
| Prepaid Expense And Other Assets Current | - | - | - | 1 | 1 | 1 | 0 | - | 0 | - | - | - | ||||||
| Grants Receivable | 2 | 2 | 0 | - | 2 | - | - | - | - | - | - | - | ||||||
| Prepaid Expense And Other Assets | 3 | 2 | 1 | - | 1 | - | - | 0 | 0 | 0 | 0 | 2 | ||||||
| Assets Current | 14 | 17 | 22 | 26 | 21 | 24 | 25 | 20 | 24 | 31 | 21 | 23 | ||||||
| Operating Lease Right Of Use Asset | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Intangible Assets Net Excluding Goodwill | - | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | ||||||
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Assets | 14 | 18 | 23 | 27 | 22 | 25 | 26 | 21 | 25 | 32 | 21 | 24 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 4 | 2 | 3 | 2 | 2 | 2 | 1 | 3 | 4 | 4 | 4 | 3 | ||||||
| Operating Lease Liability Current | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Notes Payable Current | - | - | - | - | - | - | - | 3 | 6 | 8 | 10 | 9 | ||||||
| Embedded Derivative Fair Value Of Embedded Derivative Liability | - | - | - | - | - | - | - | - | - | - | 0 | 0 | ||||||
| Liabilities Current | 4 | 2 | 3 | 2 | 2 | 3 | 1 | 7 | 9 | 12 | 14 | 13 | ||||||
| Operating Lease Liability Noncurrent | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Long Term Notes Payable | - | - | - | - | - | - | - | - | - | - | - | 3 | ||||||
| Liabilities | 4 | 2 | 3 | 2 | 3 | 3 | 2 | 7 | 10 | 13 | 14 | 16 | ||||||
Stockholders Equity | ||||||||||||||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital Common Stock | 385 | 384 | 383 | 382 | 371 | 370 | 370 | 353 | 350 | 348 | 328 | 319 | ||||||
| Retained Earnings Accumulated Deficit | -374 | -369 | -363 | -357 | -352 | -349 | -346 | -339 | -334 | -329 | -320 | -312 | ||||||
| Treasury Stock Value | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | ||||||
| Stockholders Equity | 10 | 16 | 19 | 25 | 19 | 22 | 24 | 14 | 16 | 19 | 7 | 8 | ||||||
| Liabilities And Stockholders Equity | 14 | 18 | 23 | 27 | 22 | 25 | 26 | 21 | 25 | 32 | 21 | 24 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 800 | 800 | 800 | 800 | 800 | 800 | 800 | 800 | 800 | 800 | 800 | 800 | ||||||
| Common Stock Shares Issued | 8 | 8 | 8 | 8 | 2 | 2 | 2 | 1 | 1 | 2 | 4 | 4 | ||||||
| Shares Outstanding | 8 | 8 | 8 | 8 | 2 | 2 | 2 | 1 | 1 | 6 | 4 | 4 | ||||||
Select a line item above to chart it.
Recent filings
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialBIOVIE INC. (BIVI) — SEC Financial Statements & Analysis
BIOVIE INC. (BIVI) is a pharmaceutical preparations company, incorporated in NV. BIOVIE INC. trades on Nasdaq as: BIVI, BIVIW. BIOVIE INC. (BIVI)'s most recent SEC filing is a Form 10-K for the period ended 2026-06-30, filed with the SEC on 2026-08-13. Based on its latest SEC filing (Form 10-Q, period ending 2026-06-30), BIOVIE INC. carries a market cap of $14.06M, a P/E ratio of -0.64x, a P/B ratio of 1.37x, an enterprise value of $5.08M, and an EV/EBITDA multiple of -0.23x. On profitability, it posts a Return on Equity (ROE) of -150.76%, a Return on Assets (ROA) of -123.27%, and a Return on Invested Capital (ROIC) of -1641.23%. Per share, it reports EPS of $-3.05, diluted EPS of $-3.05, free cash flow per share of $-2.63, and a dividend per share of $0.00. Over the trailing year, it posted net income growth of 25.83% year-over-year and EPS growth of -74.34% year-over-year. On the balance sheet, it maintains a current ratio of 3.59x, a quick ratio of 3.59x, working capital of $9.85M, a debt-to-equity ratio of 0.39x, a debt ratio of 0.28, an interest coverage ratio of -1138.85x, free cash flow of $-19.02M (TTM), and net debt of $-8.98M. Figures sourced from SEC EDGAR.
- Market Cap
- $14.06M
- P/E TTM
- -0.64x
- EPS TTM
- $-3.05
- P/B TTM
- 1.37x
- ROE TTM
- -150.76%
- ROA TTM
- -123.27%
- Debt To Equity
- 0.39x
- Free Cash Flow TTM
- $-19.02M
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is BIOVIE INC. in?
BIOVIE INC. (BIVI) operates in the Pharmaceutical Preparations industry.
What exchange does BIVI trade on?
BIOVIE INC. (BIVI) trades on the Nasdaq.
Where is BIOVIE INC. incorporated?
BIOVIE INC. is incorporated in NV.
When was BIOVIE INC. (BIVI)'s most recent SEC filing?
BIOVIE INC. (BIVI)'s most recent SEC filing is a Form 10-K for the period ended 2026-06-30, filed with the SEC on 2026-08-13.
What is BIVI's market cap?
BIOVIE INC. (BIVI) has a market capitalization of $14.06M as of 2026-06-30.
What is BIVI's EPS (earnings per share)?
BIOVIE INC. (BIVI)'s trailing twelve month EPS is $-3.05 as of 2026-06-30.
What is BIVI's ROE (return on equity)?
BIOVIE INC. (BIVI)'s trailing twelve month Return on Equity (ROE) is -150.76% as of 2026-06-30.
What is BIVI's ROA (return on assets)?
BIOVIE INC. (BIVI)'s trailing twelve month Return on Assets (ROA) is -123.27% as of 2026-06-30.
What is BIVI's ROIC (return on invested capital)?
BIOVIE INC. (BIVI)'s trailing twelve month Return on Invested Capital (ROIC) is -1641.23% as of 2026-06-30.
What is BIVI's EV/EBITDA?
BIOVIE INC. (BIVI)'s trailing twelve month EV/EBITDA is -0.23x as of 2026-06-30.